






# NovoSorb® BTM is an implantable bilayered synthetic dermal matrix for the reconstruction of complex wounds.





### Robust in the presence of infection<sup>2,4</sup>

Does not act as a food source for infections, often allowing retention while the infection is treated.











4 months

Diabetic foot ulcer with exposed tendons. An infection in the wound at 2 weeks was able to be treated while NovoSorb BTM was retained in place. Full integration, graft take and wound closure were achieved.



# Designed to minimise contracture over functionally important areas and improve cosmesis (uniformity of texture)<sup>5</sup>

Compared with primary skin grafting.







Post debridement

Integrated

3 months

Radical debridement for necrotising fasciitis exposed deep structures of the neck. Reconstruction with NovoSorb BTM and skin graft resulted in a good aesthetic and functional outcome with minimal contracture.



## Generation of a neodermis over exposed tendons and bones 1,4,5

Can offer alternative treatment for complex wounds.







Integrating



4 months

Traumatic crush injury with exposed tibia and fibula devoid of periosteum. After a failed free flap, NovoSorb BTM provided robust coverage to support definitive closure, allowing the patient to return to work in the military.



## **Dermal repair to support** limb salvage<sup>6</sup>

By creating a vascularised neodermis for definitive closure










Application



A traumatic crush injury resulted in full avulsion of dorsal and plantar soft tissue, sparing the heel. To avoid amputation and preserve ambulation, NovoSorb BTM was used to generate a neodermis which provided robust coverage for definitive closure.







NovoSorb BTM is indicated for full or deep partial thickness burns and wounds, surgical and reconstructive wounds and traumatic wounds.

#### Intended use:

To temporise dermal injuries, where the dermis has been decimated or lost, and to facilitate dermal repair by providing temporary wound closure and a scaffold for the generation of a neodermis.

Refer to the Instructions For Use (IFU) for full device details including indications, contraindications, warnings and precautions.



#### Manufacturer

PolyNovo Biomaterials Pty Ltd 2/320 Lorimer Street, Port Melbourne, Victoria 3207 Australia T +61 3 8681 4050 info@polynovo.com

#### **EMEA Head Office**

PolyNovo UK Ltd 10 John Street London, WC1N 2EB United Kingdom T +44 7961 243404 info.uk@polynovo.com

#### **EU Authorised Rep**

EMERGO EUROPE Westervoortsedijk 60 6827 AT Arnhem The Netherlands

#### **UK Responsible Person**

Emergo Consulting (UK) Limited c/O Cr360 – UL International Compass House, Vision Park Histon Cambridge CB24 9BZ United Kingdom

References: 1. Wagstaff MJD, Schmitt BJ, Coghlan P, Finkemeyer JP, Caplash Y, Greenwood JE. A biodegradable polyurethane dermal matrix in reconstruction of free flap donor sites: a pilot study. ePlasty 2015; 15:102–18. 2. Greenwood JE, Dearman BL. Comparison of a sealed, polymer foam biodegradable temporizing matrix against Integra® dermal regeneration template in a porcine wound model. J Burn Care Res. 2012; 33:163–73. 3. Dearman BL, Li A, Greenwood JE. Optimization of a polyurethane dermal matrix and experience with a polymer-based cultured composite skin. J Burn care Res. 2014; 35(5): 437–48. 4. Greenwood JE, Schmitt BJ, Wagstaff MJD. Experience with a synthetic bilayer Biodegradable Temporising Matrix in significant burn injury. Burns Open. 2018;2(1):17–34. 5. Wagstaff MJD, Salna IM, Caplash Y, Greenwood JE. Biodegradable Temporising Matrix (BTM) for the reconstruction of defects following serial debridement for necrotising fasciitis: A case series. Burns Open. 2019; 3:12–30. 6. Data on file.